- Home
- PROK vs ACHV Comparison
PROK vs ACHV Comparison
Compare PROK & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- ACHV
- Stock Information
- Founded
- PROK 2015
- ACHV N/A
- Country
- PROK United States
- ACHV United States
- Employees
- PROK N/A
- ACHV N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- PROK Health Care
- ACHV Health Care
- Exchange
- PROK Nasdaq
- ACHV Nasdaq
- Market Cap
- PROK 85.5M
- ACHV 72.5M
- IPO Year
- PROK N/A
- ACHV N/A
- Fundamental
- Price
- PROK $3.27
- ACHV $2.71
- Analyst Decision
- PROK Buy
- ACHV Strong Buy
- Analyst Count
- PROK 5
- ACHV 3
- Target Price
- PROK $6.25
- ACHV $14.33
- AVG Volume (30 Days)
- PROK 37.1M
- ACHV 1.9M
- Earning Date
- PROK 08-08-2025
- ACHV 08-12-2025
- Dividend Yield
- PROK N/A
- ACHV N/A
- EPS Growth
- PROK N/A
- ACHV N/A
- EPS
- PROK N/A
- ACHV N/A
- Revenue
- PROK $306,000.00
- ACHV N/A
- Revenue This Year
- PROK $85.21
- ACHV N/A
- Revenue Next Year
- PROK N/A
- ACHV N/A
- P/E Ratio
- PROK N/A
- ACHV N/A
- Revenue Growth
- PROK N/A
- ACHV N/A
- 52 Week Low
- PROK $0.46
- ACHV $1.84
- 52 Week High
- PROK $7.13
- ACHV $5.31
- Technical
- Relative Strength Index (RSI)
- PROK 62.08
- ACHV 50.08
- Support Level
- PROK $3.17
- ACHV $2.25
- Resistance Level
- PROK $4.05
- ACHV $2.85
- Average True Range (ATR)
- PROK 1.00
- ACHV 0.18
- MACD
- PROK 0.13
- ACHV 0.05
- Stochastic Oscillator
- PROK 43.10
- ACHV 90.36
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.